The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that the Company, for the first time, has exhibited a commercial version of EndoDrill® GI at the 7th Nordic EUS Meeting in Copenhagen. The meeting was aimed at BiBB’s target group, EUS endoscopists, and several participants expressed interest in the EndoDrill® technology. Demonstrations of the EndoDrill® GI system resulted in explicit requests to clinically evaluate the product from several new hospitals in Scandinavia and Europe.
For the first time, BiBB exhibited a commercial version of EndoDrill® GI at the 7th Nordic EUS Meeting in Copenhagen on September 19-20. It was a meeting for Nordic EUS endoscopists with selected guest speakers. The exhibition was attended by doctors from the Nordic region, as well as from other parts of the world, together with representatives from the industry. BiBB was present with founder Dr. Charles Walther and CEO Fredrik Lindblad, and EndoDrill® GI was demonstrated to curious endoscopists at the booth. Visitors were impressed by the EndoDrill® technology, and several new hospitals immediately expressed interest in clinically evaluating EndoDrill® GI. This offers the opportunity to gain additional clinical experience from various users in Europe, in addition to ongoing clinical trials at six hospitals in Europe and the USA.
“There were interesting discussions with EUS endoscopists about EndoDrill® GI, and it is very encouraging that they seem to spontaneously like the concept of our powered rotational needle biopsy. As a result of the interest, we will now expand the clinical evaluation in Europe with more hospitals, including some of Europe’s largest EUS centers,” says Dr. Charles Walther, founder and CMO of BiBB.
About EndoDrill® GI
EndoDrill® GI is the world’s first market-cleared electric-driven biopsy instrument for endoscopic ultrasound (EUS). The instrument is used for EUS-guided tissue sampling for all indications in the gastrointestinal tract, e.g. pancreas, stomach, oesophagus, lymph nodes, and liver. EndoDrill® GI received FDA 510(k) clearance in the US in 2023 and CE approval in Europe in early 2024. The product is being evaluated clinically in the US and Europe with a planned launch in Sweden later in 2024.
This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.
For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com
About BiBB
The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill®, a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill® instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill® GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. Thus EndoDrill® is the first cleared electric endoscopic biopsy system in both the US and Europe. The EndoDrill® system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.